EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0J9P: Incyte Ord Shs

24 Aug 2026
LAST:

127.6

CHANGE:
 1.04		OPEN:
127.0		HIGH:
129.0		ASK:
0.0		VOLUME:
988
CHG(%):
0.81		PREV:
128.7		LOW:
126.3		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Aug 26127.0129.0126.3127.6988
21 Aug 26126.8130.7126.2128.7471
20 Aug 26129.0129.8125.1128.3856
19 Aug 26128.0128.0123.8127.51.0K
18 Aug 26121.5124.9121.3123.8398
17 Aug 26116.8123.7115.0123.7263
14 Aug 26122.2124.0116.0120.2522
13 Aug 26118.7124.6118.7120.5174
12 Aug 26125.6125.6119.0120.61.1K
11 Aug 26118.9124.0118.5121.1409

PROFILE

Name:Incyte Ord Shs
About:Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Address:1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Website:https://www.incyte.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.31 
Price to Sales:4.56 
Price to Book:4.07 
Profit Margin:0.28 
Operating Margin:0.42 
Return on Assets:0.17 
Return on Equity:0.31 
EPS Ratio:4.20 
Revenue:5.82B 
EBITDA:1.942B 
Shares:212.81M 
Market Cap:27.159B 

TECHNICAL INDICATORS

MA5:127.170.4%
MA10:124.202.8%
MA20:123.093.7%
MA50:116.639.4%
MA100:107.3518.9%
MA200:103.6623.1%
STO9:70.38
STO14:77.80
RSI14:67.99 
WPR14:-8.71 
MTM14:7.12
ROC14:0.06 
ATR:5.51 
Week High:130.732.4%
Week Low:115.0011.0%
Month High:134.255.2%
Month Low:114.0023.1%
Year High:134.255.2%
Year Low:81.5056.6%
Volatility:18.02